Sagimet Gets Wall Street Upgrade After China Acne Data and U.S. Trial Clearance
Barclays says Sagimet’s dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027.
Barclays says Sagimet’s dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027.
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.
Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data.